SAB Biotherapeutics

SAB Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel immunotherapies utilizing fully human polyclonal antibodies. Leveraging advanced genetic engineering and antibody science, the company has developed a platform capable of rapidly producing natural, highly targeted, and potent human polyclonal immunotherapies at commercial scale. Through superior genetic engineering, they have created the DiversitAb™ platform to harness the natural human antibody immune response. Their innovative therapeutic engine can produce drugs (human polyclonal antibodies) for a variety of pathogens to address modern health challenges such as seasonal influenza, type 1 diabetes, and cancer.